Benitec Biopharma Reports on Shareholder Vote

Ticker: BNTC · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateDec 6, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001 B
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

Benitec Biopharma held a shareholder vote on Dec 4th, details filed today.

AI Summary

Benitec Biopharma Inc. filed an 8-K on December 6, 2024, reporting on a matter submitted to a vote of its security holders on December 4, 2024. The filing details the company's principal executive offices located at 3940 Trust Way, Hayward, California.

Why It Matters

This filing indicates a significant event where shareholder approval was sought, which could impact the company's strategic direction or operational decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial distress or major operational changes.

Key Players & Entities

FAQ

What was the specific matter submitted to a vote of Benitec Biopharma's security holders on December 4, 2024?

The filing states that the report is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and concerns the 'Submission of Matters to a Vote of Security Holders,' but the specific details of the vote are not provided in this excerpt.

What is the principal executive office address for Benitec Biopharma Inc.?

The principal executive offices are located at 3940 Trust Way, Hayward, California 94545.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on December 4, 2024.

What is Benitec Biopharma Inc.'s state of incorporation?

Benitec Biopharma Inc. is incorporated in Delaware.

What is the SIC code for Benitec Biopharma Inc.?

The Standard Industrial Classification (SIC) code for Benitec Biopharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-12-06 17:01:59

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: December 6, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing